PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Stopped Investigator request to no longer pursue this study. Lack of support from drug company. This trial never opened. Withdrew IND.

Conditions

• Diffuse Large B Cell Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Follicular

Interventions

• DRUG: Retifanlimab, INCAGN02385, INCAGN02390

Sponsor

University of Alabama at Birmingham